Cohance Lifesciences Ltd Share Price
As on 13 June 2026 at 01:11 IST
Cohance Lifesciences Q1 FY26 Results:
Net profit for the period declined 35% to ₹49 crores in Q1 FY26, from ₹75 crores in Q1 FY25. Total income for the quarter increased 11% year-on-year to ₹564 crores from ₹508 crores.
About Cohance Lifesciences Ltd
Suven Pharmaceuticals Ltd is a prominent Indian pharmaceutical company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and speciality chemicals. It operates in the pharmaceutical sector, focusing on contract research and manufacturing services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company was established in the year 1989. The headquarters of Suven Pharmaceuticals is located in Hyderabad, Telangana, India. The company’s main products include APIs, intermediates, and specialty chemicals. It also offers a variety of other pharmaceutical services, such as formulation development and clinical supplies manufacturing. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-11.59%
Over 6 Months
-20.21%
Over 1 Year
-57.75%
Over 3 Years
-10.86%
Cohance Lifesciences Ltd Summary
Close ₹423.45
Open ₹428
High ₹428
Low ₹421.05
Volume 4,11,443
Net Turnover (in Cr) ₹17.43
52Wk High ₹1,121.15
52Wk Low ₹266.70
52Wk High / Low
266.70
1,121.15
Cohance Lifesciences Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹16,199.81
EPS (TTM) 6.54
Book Value (BV) 117.11
Div. Yield -
P/E (TTM) 70.79
Price/Book Value 3.61
Delivery % 46.29 %
Face Value 1
Key Ratios
PE Ratio 108.70
PB Ratio 12.75
EV to Sales 27.07
PEG Ratio -13.04
ROA 11.25
ROE 12.51
Debt-Equity 0.04
Net Profit Margin 24.85
Operating Profit Margin 38.09
Cohance Lifesciences Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,256.14 | 1,113.26 | 1,386.69 | 1,412.60 | 1,023.96 |
| Total Expenses | 912.22 | 707.59 | 826.96 | 786.12 | 610.02 |
| Profit Before Tax | 343.92 | 405.67 | 559.73 | 667.59 | 467.67 |
| Profit After Tax | 264.77 | 300.28 | 411.29 | 453.80 | 362.34 |
| Operating Profit After Depreciation | 356.27 | 413.12 | 565.17 | 632.71 | 423.08 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,714.20 | 669.73 | 663.33 | 534.19 | 441.34 |
| Total Non Current Assets | 2,143.16 | 990.90 | 954.70 | 701.66 | 909.69 |
| Total Current Assets | 888.59 | 1,263.19 | 1,011.05 | 1,127.93 | 564.79 |
| Total Assets | 3,031.75 | 2,254.09 | 1,965.74 | 1,829.59 | 1,474.48 |
| Total Shareholder's Fund | 1,696.58 | 2,050.66 | 1,735.18 | 1,527.18 | 1,180.80 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 288.16 | 358.48 | 457.20 | 330 | 382.55 |
| Net Cash Used In Investing Activities | -253.31 | -362.25 | -195.01 | -136.21 | -311.40 |
| Net Cash Used In Financing Activities | 3.32 | -13.80 | -241.95 | -156.41 | -75.66 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,147.49 | 1,107.96 | 1,374.63 | 1,508.01 | 1,023.96 |
| Total Expenses | 796.14 | 707.54 | 795.24 | 785.56 | 609.98 |
| Profit Before Tax | 351.35 | 400.42 | 579.39 | 722.45 | 413.98 |
| Profit After Tax | 271.71 | 296.47 | 432.60 | 558.10 | 308.65 |
| Operating Profit After Depreciation | 359.35 | 407.87 | 592.14 | 728.68 | 423.12 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 685.57 | 669.73 | 512.03 | 534.19 | 441.33 |
| Total Non Current Assets | 1,879.05 | 990.65 | 1,003.21 | 695.93 | 794.13 |
| Total Current Assets | 708.76 | 1,224.23 | 955.12 | 1,108.96 | 564.69 |
| Total Assets | 2,587.81 | 2,214.88 | 1,958.33 | 1,804.89 | 1,358.83 |
| Total Shareholder's Fund | 2,315.55 | 2,028.35 | 1,749.38 | 1,520.69 | 1,065.18 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 301.03 | 376.20 | 492.82 | 269.89 | 329.73 |
| Net Cash Used In Investing Activities | -320.94 | -362.40 | -236.86 | -90.36 | -257.66 |
| Net Cash Used In Financing Activities | 20.81 | -39.99 | -243.14 | -156.41 | -76.55 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 619.12 | 544.55 | 555.57 | 549.31 | 840.42 |
| Total Expenses | 520.44 | 449.20 | 434.62 | 437.30 | 611.20 |
| Profit Before Tax | 19.91 | 40.60 | 83.77 | 62.76 | 160.87 |
| Profit After Tax | 8.31 | 29.02 | 66.39 | 46.40 | 117.15 |
| Operating Profit after Depreciation | 96.84 | 101.51 | 136.55 | 126.18 | 241.27 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 567.55 | 481.58 | 497.79 | 483.58 | 768.57 |
| Total Expenses | 450.98 | 378.80 | 366.93 | 379.38 | 545.80 |
| Profit Before Tax | 56.44 | 65.43 | 120.72 | 71.04 | 165.60 |
| Profit After Tax | 34.56 | 47.29 | 94.29 | 52.57 | 122.77 |
| Operating Profit after Depreciation | 115.78 | 108.90 | 157.16 | 117.30 | 230.96 |
Cohance Lifesciences Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 420.33
S2 417.22
S3 413.38
Pivot 424.17
R1 427.28
R2 431.12
R3 434.23
Moving Average
20 SMA 428.15
50 SMA 407.08
100 SMA 372.08
200 SMA 554.02
Cohance Lifesciences Ltd Corporate Actions
Cohance Lifesciences Ltd
₹5.0/Share
Announcement Date 09 Sep 2022
Record Date 12 Sep 2022
Div Yield 500%
Cohance Lifesciences Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
Cohance Lifesciences Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| ICICI Pru P.H.D Fund | 4.37% |
| DSP Healthcare Fund | 4.15% |
| SBI Multi Asset Allocation Fund | 1.23% |
| DSP Aggressive Hybrid Fund | 1.05% |
| DSP Flexi Cap Fund | 0.90% |
Cohance Lifesciences Ltd News
Cohance Lifesciences to discuss results
On 12 May 2026
07 May 2026, 11:01 am
Cohance Lifesciences Ltd leads gainers in 'A' group
AGI Greenpac Ltd, Black Box Ltd, Electronics Mart India Ltd and Epack Durable Ltd are among the other gainers in the BSE's 'A' group today, 28 April 2026.
28 Apr 2026, 12:00 pm
Cohance Lifesciences Ltd leads gainers in 'A' group
India Cements Ltd, Tanla Platforms Ltd, Blue Jet Healthcare Ltd and Epack Durable Ltd are among the other gainers in the BSE's 'A' group today, 27 April 2026.
27 Apr 2026, 12:00 pm
Cohance Lifesciences soars after appointing Umang Vohra as chairman & CEO.
Cohance Lifesciences surged 18.03% to Rs 425.60 after the company's board approved the appointment of Umang Vohra as chairman, with effect from 1 May 2026 and group chief executive officer (CEO) with effect from 20 May 2026 for period of five years.
27 Apr 2026, 10:00 am
Board of Cohance Lifesciences approves change in chairman
At meeting held on 27 April 2026
27 Apr 2026, 09:06 am
Cohance Lifesciences Ltd Stock Analysis
- Annual revenue for Cohance Lifesciences Ltd increased by 3.57% to ₹1,147.49 crore in FY 2025 from ₹1,107.96 crore in FY 2024.
- Annual Net Profit for Cohance Lifesciences Ltd decreased by 8.35% to ₹271.71 crore in FY 2025 from ₹296.47 crore in FY 2024.
- Promoter Shareholding in Cohance Lifesciences Ltd remains unchanged by 0.00% in the most recent quarter, from 57.49% in December 2025 to 57.49% in March 2026.
- Cohance Lifesciences Ltd delivered a 1-year return of -57.75% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- Cohance Lifesciences Ltd share price moved up by 1.32% from its previous close of INR ₹423.45. The latest Cohance Lifesciences Ltd share price is INR ₹429.05.
- Cohance Lifesciences Ltd share price today has been at a low of 425.70 and a high of 434.95. Over the past 52 weeks, the Cohance Lifesciences Ltd share price has seen a low of 266.70 and a high of 1,121.15.
About Cohance Lifesciences Ltd
Suven Pharmaceuticals Ltd, founded in 1989, is a prominent Indian pharmaceutical company which is headquartered in Hyderabad, Telangana. The company is a key player in the pharmaceutical industry. It specializes in active pharmaceutical ingredients (APIs) and specialty chemicals. The company also provides contract research and manufacturing services.
Led by Executive Chairperson Annaswamy Vaidheesh, Suven Pharmaceuticals operates with Berhyanda Limited as its majority stakeholder, holding a 50.10% stake. The company caters to pharmaceutical, biotechnology, and chemical clients worldwide. While its registered office is located in Mumbai, Maharashtra, its registrars are based in Hyderabad. They also have a team of managerial promoters who manage the operations of the company. They are
Suven Pharmaceuticals is not the largest player in terms of market capitalization. However, the company has earned a solid reputation through its reliable operations and strong financial stability. It distinguishes itself through an unwavering focus on customer needs and quality excellence in pharmaceutical solutions. Their commitment to innovation and customer satisfaction continues to drive their competitive advantage.
Drawing on decades of pharmaceutical experience, Suven has cemented its position as a dependable industry partner. Their expertise in research and manufacturing enables them to maintain a strong market presence. It also helps the company deliver excellence in pharmaceutical manufacturing and research services.
A cornerstone of Suven's success lies in its robust research and development initiatives. The company's R&D investments have yielded advanced manufacturing processes and industry-leading products. This focus on innovation has enabled Suven to develop improved APIs and intermediates, which are crucial components in creating effective and safe pharmaceutical products.
Another key area where Suven has made a notable impact is through its Contract Research and Manufacturing Services (CRAMS). The company offers comprehensive solutions to global pharmaceutical and chemical companies. This includes custom synthesis and commercial manufacturing of intermediates and formulations. These CRAMS offerings have proven invaluable to clients, enabling them to bring new drugs to market more efficiently and cost-effectively.
Quality excellence stands as a cornerstone of Suven Pharmaceuticals' contributions to the pharmaceutical sector. The company maintains rigorous quality control measures and strictly adheres to regulatory standards. This ensures its products meet the highest safety and efficacy benchmarks. Their advanced manufacturing facilities, operating under Good Manufacturing Practices (GMP), have helped build a strong reputation and deep trust among clients and stakeholders.
Beyond its pharmaceutical accomplishments, Suven Pharmaceuticals plays a vital role in economic development. The company provides stable and rewarding employment opportunities to thousands of individuals. As a result, it has become a significant contributor to local economies. The employment generated by the company has also positively impacted communities. It has improved the quality of life for many families in the regions where it operates.
Through its diverse contributions, Suven Pharmaceuticals makes a meaningful impact on the pharmaceutical industry. It also positively influences society and the environment. The strong financial performance of Suven Pharmaceuticals highlights its significant impact on the pharmaceutical sector. The company has consistently delivered robust financial results, demonstrating its stability and resilience. Its prudent financial management and strategic investments have contributed to its growth. These efforts have also supported the company's sustained profitability.
The company's impact is also reflected in its commitment to social responsibility. Suven Pharmaceuticals has undertaken various initiatives to support community development and social welfare. These include educational programs and environmental sustainability projects. Suven Pharmaceuticals believes in giving back to society. The company has made significant contributions to improving the quality of life for many people.
Suven Pharmaceuticals enhances its impact on the pharmaceutical sector through strategic partnerships. Its collaborations further amplify its contributions to the industry. The company has formed alliances with various pharmaceutical and chemical companies. These partnerships help enhance its service offerings and expand its reach.
Suven Pharmaceuticals Ltd has made a profound impact on the pharmaceutical sector. The company's focus on innovation, quality, and sustainability has earned it a strong reputation in the industry. The company's contributions extend beyond its products and services to its role in customer satisfaction. Suven Pharmaceuticals has achieved strong financial performance over the years through their relentless dedication towards excellence. Its strategic partnerships have further contributed to its sustained growth and success.
Led by Executive Chairperson Annaswamy Vaidheesh, Suven Pharmaceuticals operates with Berhyanda Limited as its majority stakeholder, holding a 50.10% stake. The company caters to pharmaceutical, biotechnology, and chemical clients worldwide. While its registered office is located in Mumbai, Maharashtra, its registrars are based in Hyderabad. They also have a team of managerial promoters who manage the operations of the company. They are
- V Prasada Raju
- Pankaj Patwari
- Shweta Jalan
- Matangi Gowrishankar
Suven Pharmaceuticals is not the largest player in terms of market capitalization. However, the company has earned a solid reputation through its reliable operations and strong financial stability. It distinguishes itself through an unwavering focus on customer needs and quality excellence in pharmaceutical solutions. Their commitment to innovation and customer satisfaction continues to drive their competitive advantage.
Drawing on decades of pharmaceutical experience, Suven has cemented its position as a dependable industry partner. Their expertise in research and manufacturing enables them to maintain a strong market presence. It also helps the company deliver excellence in pharmaceutical manufacturing and research services.
The Contribution of Suven Pharmaceuticals Limited to the Pharmaceutical Sector
Since its establishment in 1989, Suven Pharmaceuticals Ltd. has emerged as a significant player in the pharmaceutical industry, both in India and globally. The company has built its reputation through expertise in developing and manufacturing active pharmaceutical ingredients, coupled with an unwavering commitment to quality products and services.A cornerstone of Suven's success lies in its robust research and development initiatives. The company's R&D investments have yielded advanced manufacturing processes and industry-leading products. This focus on innovation has enabled Suven to develop improved APIs and intermediates, which are crucial components in creating effective and safe pharmaceutical products.
Another key area where Suven has made a notable impact is through its Contract Research and Manufacturing Services (CRAMS). The company offers comprehensive solutions to global pharmaceutical and chemical companies. This includes custom synthesis and commercial manufacturing of intermediates and formulations. These CRAMS offerings have proven invaluable to clients, enabling them to bring new drugs to market more efficiently and cost-effectively.
Quality excellence stands as a cornerstone of Suven Pharmaceuticals' contributions to the pharmaceutical sector. The company maintains rigorous quality control measures and strictly adheres to regulatory standards. This ensures its products meet the highest safety and efficacy benchmarks. Their advanced manufacturing facilities, operating under Good Manufacturing Practices (GMP), have helped build a strong reputation and deep trust among clients and stakeholders.
Beyond its pharmaceutical accomplishments, Suven Pharmaceuticals plays a vital role in economic development. The company provides stable and rewarding employment opportunities to thousands of individuals. As a result, it has become a significant contributor to local economies. The employment generated by the company has also positively impacted communities. It has improved the quality of life for many families in the regions where it operates.
Through its diverse contributions, Suven Pharmaceuticals makes a meaningful impact on the pharmaceutical industry. It also positively influences society and the environment. The strong financial performance of Suven Pharmaceuticals highlights its significant impact on the pharmaceutical sector. The company has consistently delivered robust financial results, demonstrating its stability and resilience. Its prudent financial management and strategic investments have contributed to its growth. These efforts have also supported the company's sustained profitability.
The company's impact is also reflected in its commitment to social responsibility. Suven Pharmaceuticals has undertaken various initiatives to support community development and social welfare. These include educational programs and environmental sustainability projects. Suven Pharmaceuticals believes in giving back to society. The company has made significant contributions to improving the quality of life for many people.
Suven Pharmaceuticals enhances its impact on the pharmaceutical sector through strategic partnerships. Its collaborations further amplify its contributions to the industry. The company has formed alliances with various pharmaceutical and chemical companies. These partnerships help enhance its service offerings and expand its reach.
Suven Pharmaceuticals Ltd has made a profound impact on the pharmaceutical sector. The company's focus on innovation, quality, and sustainability has earned it a strong reputation in the industry. The company's contributions extend beyond its products and services to its role in customer satisfaction. Suven Pharmaceuticals has achieved strong financial performance over the years through their relentless dedication towards excellence. Its strategic partnerships have further contributed to its sustained growth and success.
FAQ’s
What is the share price of Cohance Lifesciences Ltd today?
Cohance Lifesciences Ltd share price as on 12 Jun 2026 is ₹ 429.05
What is the Market Cap of Cohance Lifesciences Ltd?
The market cap of Cohance Lifesciences Ltd stock is ₹16,199.81 Cr.
What is the PE Ratio of Cohance Lifesciences Ltd?
The Price to Earnings (P/E) Ratio of Cohance Lifesciences Ltd is 108.70
What is the PB Ratio of Cohance Lifesciences Ltd?
The Price to Book (P/B) Ratio of Cohance Lifesciences Ltd is 12.75
What is the 52 week high of Cohance Lifesciences Ltd Share Price?
The 52 week high of Cohance Lifesciences Ltd share price stands at ₹1,121.15
What is the 52 week low of Cohance Lifesciences Ltd Share Price?
The 52 week low of Cohance Lifesciences Ltd share price stands at ₹266.70
How can I buy shares of Cohance Lifesciences Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Cohance Lifesciences Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
